KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Payables: 2020-2024

Historic Payables for Recursion Pharmaceuticals (RXRX) over the last 5 years, with Dec 2024 value amounting to $21.6 million.

  • Recursion Pharmaceuticals' Payables rose 516.59% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.9 million, marking a year-over-year increase of 426.46%. This contributed to the annual value of $21.6 million for FY2024, which is 441.14% up from last year.
  • According to the latest figures from FY2024, Recursion Pharmaceuticals' Payables is $21.6 million, which was up 441.14% from $4.0 million recorded in FY2023.
  • Recursion Pharmaceuticals' 5-year Payables high stood at $21.6 million for FY2024, and its period low was $2.1 million during FY2020.
  • For the 3-year period, Recursion Pharmaceuticals' Payables averaged around $10.1 million, with its median value being $4.7 million (2022).
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Payables decreased by 14.71% in 2023, and later skyrocketed by 441.14% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Payables (Yearly) stood at $2.1 million in 2020, then soared by 35.49% to $2.9 million in 2021, then skyrocketed by 60.98% to $4.7 million in 2022, then declined by 14.71% to $4.0 million in 2023, then spiked by 441.14% to $21.6 million in 2024.